Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

AHN Autoimmunity Institute launches novel research initiative aimed at paving way for new treatments, cure


News provided by

Allegheny Health Network

Jun 11, 2024, 10:00 ET

Share this article

Share toX

Share this article

Share toX

Allegheny Health Network
Allegheny Health Network

'PURPOSE' is an unprecedented effort to advance the understanding of 'relapsing polychondritis' and improve treatments for those living with the rare autoimmune disease and related conditions

PITTSBURGH, June 11, 2024 /PRNewswire-PRWeb/ -- The Allegheny Health Network (AHN) Autoimmunity Institute, in partnership with the Relapsing Polychondritis Foundation, today announced that it has launched a nationwide, first-of-its-kind study, known as 'Patients' Universal Relapsing Polychondritis Open Specimen Endeavor' (PURPOSE).

Led by AHN, PURPOSE is an unprecedented effort to create a biospecimen repository, known as a biobank, including clinical data and blood samples from patients across the country who have been diagnosed with relapsing polychondritis (RP). Once enough specimens are collected, leading researchers at the AHN Autoimmunity Institute and investigators nationwide – and eventually around the world – will have access to the information as part of the collective effort to advance diagnostic accuracy, monitoring and treatment of relapsing polychondritis and other autoimmune diseases.

"If we can uncover answers for one condition, we know these insights may have a ripple effect – propelling research forward across the entire spectrum of autoimmunity."

Post this

Relapsing polychondritis (RP) is a rare autoimmune disease type that affects multiple organ systems, causing inflammation most commonly of the ears, nose, joints and airways. It can also affect the eyes, skin and heart, as well as the neurological, vestibular and vascular systems. While its incidence is rare, impacting fewer than 5,000 people in the U.S., many believe it is underdiagnosed given there is no diagnostic test for RP.

Without an accurate diagnosis, needed treatments may be delayed, increasing the likelihood of long-term complications, says Joseph Ahearn, MD, the study's principal investigator and chair of the AHN Autoimmunity Institute.

"The key to developing a laboratory test that detects RP is the discovery of informative RP biomarkers, or biological molecules in the blood that reveal abnormal processes and simplify diagnosis," said Dr. Ahearn. "Along with our longtime partners at the Relapsing Polychondritis Foundation, we are so pleased to be leading this charge to make breakthrough biomarker discoveries through the collection of biological samples from patients who are living with RP."

Physician-scientists within the Autoimmunity Institute have been highly successful in the commercialization of laboratory tests for the diagnosis, monitoring and prognosis of autoimmune diseases. Dr. Ahearn and Susan Manzi, MD, also of the Autoimmunity Institute, helped design Avise-SLE™– a blood test to help clinicians diagnose lupus with greater ease and accuracy. Avise-SLE, which became commercially available in 2012, uses one blood sample from a patient to check for five distinct biomarkers that help to rule-in the diagnosis of systemic lupus erythematosus while ruling out other rheumatic diseases.

"If we can uncover answers for one condition, we know these insights may have a ripple effect – propelling research forward across the entire spectrum of autoimmunity. This aptly named project offers promise not just for patients with RP, but for all people living with autoimmune diseases," said Dr. Manzi, chair of the AHN Medicine Institute, director of the AHN Autoimmunity Institute's Lupus Center of Excellence and medical director for the Lupus Foundation of America's board of directors.

PURPOSE offers a new model for research in that participating patients are engaged directly by AHN versus having to be connected through their physician or health system. According to Dr. Ahearn, this concept of reaching patients where they live was accelerated by the COVID-19 pandemic, given the increase in use of telemedicine. He says this direct-to-patient research concept will initially be employed to study RP, with plans to expand to lupus and other autoimmune diseases.

Patients who have a diagnosis of relapsing polychondritis, are between the ages of 18-90, and are interested in participating should send an email to [email protected]. A video visit will be scheduled with an AHN research team member to discuss the study and learn more about participation. Patients will next receive a blood collection kit in the mail and may opt to have their sample drawn either at home or at a nearby collection site. Samples will be sent directly to the PURPOSE biobank at the AHN Autoimmunity Institute. Participation is free, including no charge to the patient or their insurance provider.

"This project correlates with two of the RP Foundation's goals; empowering patients by providing them with the opportunity to actively contribute to RP-focused research and supporting clinical researchers by supplying them with valuable biological samples," said Michael Linn, director and vice chair of the RP Foundation and longtime advocate for autoimmune disease awareness, education and research. "By partnering with the PURPOSE biobank project, we hope to advance our efforts to forge the path to a cure by fueling groundbreaking autoimmune disease discoveries."

The AHN Autoimmunity Institute, founded in 2018, offers in-depth appointments during which patients often see multiple specialists during one visit. The Institute has been enthusiastically embraced by health care providers and patients who have traveled from more than 40 states, including Alaska and Hawaii. To learn more, visit http://www.ahn.org/autoimmunity.

About Allegheny Health Network

Allegheny Health Network (AHN.org) is an integrated healthcare delivery system serving the greater Western Pennsylvania region. The Network is comprised of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, an employed physician organization, home and community-based health services, a research institute and a group purchasing organization. The Network provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, cardiovascular disease, cancer care, orthopedic surgery, neurology and neurosurgery, women's health, diabetes and more. AHN employs approximately 21,000 people, has more than 2,600 physicians on its medical staff and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.

About the RP Foundation

The RP Foundation is a non-profit organization that invests in RP focused research, education and awareness programs with the goal of improving the care of those affected by relapsing polychondritis and related autoimmune diseases.

Media Contact

Candace Herrington, Allegheny Health Network, 412-951-8193, [email protected], www.ahn.org

SOURCE Allegheny Health Network

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.